A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT03136497 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Lack of enrollment

Conditions

Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG: 400mg ABT-199
DRUG: Ibrutinib
DRUG: Rituximab
DRUG: 800mg ABT-199

Sponsor

Hackensack Meridian Health

Collaborators

[object Object]
[object Object]